Clinical Trial: NCT03678883
9-ING-41 in Patients With Advanced Cancers
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Actuate Therapeutics Inc. |
| Information Provided By: | Actuate Therapeutics Inc. |
| Last Update Posted: | 2026-04-03 |
Study Overview
Brief Summary
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
Official Title
Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors
Conditions
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Intervention / Treatment
- Drug: 9-ING-41
- Drug: Gemcitabine - 21 day cycle
- Drug: Doxorubicin.
- Drug: Lomustine
- Drug: Carboplatin.
- Drug: Nab paclitaxel.
- Drug: Paclitaxel.
- Drug: Gemcitabine - 28 day cycle
- Drug: Irinotecan
Other Study ID Numbers
- 1801
Start Date (Actual)
2019-01-04
Primary Completion Date (Estimated)
2026-06
Study Completion Date (Estimated)
2026-06
Enrollment (Estimated)
350
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Actuate Therapeutics Inc. |
| Information Provided By: | Actuate Therapeutics Inc. |
| Last Update Posted: | 2026-04-03 |
Study Overview
Brief Summary
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
Official Title
Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors
Conditions
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Intervention / Treatment
- Drug: 9-ING-41
- Drug: Gemcitabine - 21 day cycle
- Drug: Doxorubicin.
- Drug: Lomustine
- Drug: Carboplatin.
- Drug: Nab paclitaxel.
- Drug: Paclitaxel.
- Drug: Gemcitabine - 28 day cycle
- Drug: Irinotecan
Other Study ID Numbers
- 1801
Start Date (Actual)
2019-01-04
Primary Completion Date (Estimated)
2026-06
Study Completion Date (Estimated)
2026-06
Enrollment (Estimated)
350
Study Type
Interventional
Phase
Phase 2